Stoke Therapeutics (STOK) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free STOK Stock Alerts $12.27 +0.72 (+6.23%) (As of 02:46 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12 at 6:38 AM | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Shares Down 6.4% May 11 at 6:41 PM | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Short Interest Up 50.3% in AprilStoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) was the target of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 8,310,000 shares, an increase of 50.3% from the April 15th total of 5,530,000 shares. Based on an average trading volume of 1,260,000 shares, the short-interest ratio is currently 6.6 days.May 11 at 4:56 AM | americanbankingnews.comFY2024 EPS Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK) Increased by HC WainwrightMay 10, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading Down 6.4%Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.4%May 10, 2024 | marketbeat.comHC Wainwright Equities Analysts Raise Earnings Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK)Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at HC Wainwright increased their FY2024 EPS estimates for Stoke Therapeutics in a research note issued to investors on Tuesday, May 7th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($2.51) perMay 10, 2024 | americanbankingnews.comHC Wainwright Equities Analysts Reduce Earnings Estimates for Stoke Therapeutics, Inc. (NASDAQ:STOK)May 9, 2024 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Forecasted to Post FY2028 Earnings of $0.17 Per ShareStoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at HC Wainwright lowered their FY2028 earnings per share estimates for Stoke Therapeutics in a research note issued to investors on Tuesday, May 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earninMay 9, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Stoke Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:STOK)May 9, 2024 | americanbankingnews.comStoke Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.53) Per Share, Wedbush Forecasts (NASDAQ:STOK)May 9, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by HC WainwrightMay 9, 2024 | americanbankingnews.comCanaccord Genuity Group Lowers Stoke Therapeutics (NASDAQ:STOK) Price Target to $20.00May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial StabilityMay 8, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by Needham & Company LLCMay 7, 2024 | finance.yahoo.comStoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...May 7, 2024 | markets.businessinsider.comBuy Rating for Stoke Therapeutics with Adjusted Price Target Amid Regulatory and Developmental ProgressMay 7, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Given New $20.00 Price Target at Canaccord Genuity GroupCanaccord Genuity Group decreased their target price on Stoke Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Tuesday.May 7, 2024 | finance.yahoo.comStoke Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 7, 2024 | marketbeat.comStoke Therapeutics' (STOK) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday.May 6, 2024 | investorplace.comSTOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | markets.businessinsider.comStoke Therapeutics Inc Q1 Loss increases, but beats estimatesMay 6, 2024 | businesswire.comStoke Therapeutics Reports First Quarter Financial Results and Provides Business UpdatesMay 3, 2024 | msn.comStoke City latest as boss outlines plan for out of contract starsMay 3, 2024 | msn.comJCB to shut Stoke-on-Trent warehouse as up to 200 workers face uncertain futureMay 1, 2024 | msn.comLiam Manning drops Matty James contract hint as Bristol City captain is ruled out of Stoke clashMay 1, 2024 | msn.comStoke City skeleton squad for next season as starting gun fires for summer transfer windowMay 1, 2024 | msn.comCatalogue of 131 Championship free agents as Stoke City prepare for summer transfer spreeMay 1, 2024 | uk.news.yahoo.comChampionship 2024/25 line-up, final day permutations, points deduction and renewed rivalries for Stoke CityApril 30, 2024 | msn.comStoke City youngster confirms exit with classy messageApril 30, 2024 | uk.news.yahoo.comRoadworks on this busy Stoke-on-Trent route spark rush-hour 'chaos'April 30, 2024 | msn.comHonest Ben Wilmot opens up on Stoke City season and who will succeed him as player of the yearApril 30, 2024 | msn.comFake Stoke-on-Trent Gas Safe engineer avoids jail after fitting boilerApril 29, 2024 | marketwatch.comStoke Therapeutics Chief Financial Officer Stephen Tulipano ResignsApril 29, 2024 | markets.businessinsider.comStoke Therapeutics CFO Stephen Tulipano Resigns; Thomas Leggett Named ReplacementApril 29, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Down to $12.41Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down to $12.41April 29, 2024 | businesswire.comStoke Therapeutics Appoints Thomas Leggett as Chief Financial OfficerApril 28, 2024 | uk.sports.yahoo.com'Need to see players' - Why Martin made five changes for defeat to StokeApril 27, 2024 | msn.comHow Steven Schumacher plans to 'not celebrate' Stoke City survivalApril 27, 2024 | ca.news.yahoo.comSouthampton 0-1 Stoke City: Potters safe after win over SaintsApril 27, 2024 | uk.news.yahoo.comStoke City team news vs Southampton as Steven Schumacher bids for repeatApril 27, 2024 | msn.comSouthampton 0-1 Stoke City: Tyrese Campbell inflicts third straight defeat on stumbling SaintsApril 27, 2024 | msn.comPete Smith's Stoke City player ratings vs Southampton as Tyrese Campbell seals survivalApril 27, 2024 | msn.comRoyal Stoke nurse who 'couldn't walk in a straight line' given devastating diagnosisApril 26, 2024 | bbc.co.ukSouthampton vs Stoke City: Pick Of The StatsApril 26, 2024 | msn.comBlinkered Stoke City told they cannot relax in frantic Championship relegation battleApril 26, 2024 | msn.comOlympic dream over Stoke City 'big asset' Bae Junho following epic shoot-outApril 26, 2024 | bbc.comStoke decide against Celtic winger transfer - gossipApril 24, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Trading 4.9% Higher Stoke Therapeutics (NASDAQ:STOK) Shares Up 4.9%April 22, 2024 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4%Stoke Therapeutics (NASDAQ:STOK) Shares Down 4.4%April 19, 2024 | yahoo.comStoke-on-Trent to host its first comedy festivalApril 19, 2024 | msn.comStoke City predicted starting XI vs Plymouth as Steven Schumacher weighs up old boys' claims Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover STOK Media Mentions By Week STOK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STOK News Sentiment▼0.200.57▲Average Medical News Sentiment STOK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STOK Articles This Week▼295▲STOK Articles Average Week Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GHRS News OLMA News CALT News ZYME News PHAT News PHAR News LYEL News ORIC News IGMS News SLN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STOK) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
